Core Viewpoint - Shanghai Sanyou Medical Equipment Co., Ltd. has received approval from the National Medical Products Administration for the JAZZ System spinal internal fixation connector system, marking a significant step in the company's internationalization strategy and enhancing its competitive advantage in the spinal product market [1][3]. Medical Device Registration Details - Product Name: Spinal Internal Fixation Connector System JAZZ System [1] - Registration Number: National Medical Device Registration No. 20253130302 [1] - Registrant: Implanet Company [1] - Agent: Shanghai Sanyou Medical Equipment Co., Ltd. [1] - Applicable Scope: The system is suitable for spinal posterior fixation surgery for thoracolumbar (T1-L5) segments, providing binding fixation for segments unsuitable for pedicle screws [1]. - Registration Validity: From July 10, 2025, to July 9, 2030 [2]. - Composition: The system consists of straps and connectors, sterilized by irradiation with a shelf life of 5 years [2]. Impact on the Company - The introduction of Implanet's advanced JAZZ series products enriches the company's non-fusion spinal product line and enhances its competitive advantage [3]. - The product complements the company's innovative spinal fixation systems, providing a more comprehensive and advanced treatment solution for clinical doctors [3]. - This move is a crucial part of the company's international strategy, successfully bringing Implanet's JAZZ series products to the domestic market, thereby strengthening its market competitiveness and overall strength [3].

Group 1: Drug Procurement and Regulations - The National Healthcare Security Administration has initiated the 11th batch of national drug centralized procurement, with 55 varieties included in the reporting range [1] - The procurement rules emphasize principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and avoiding internal competition" [1] - Only mature "old drugs" that have been on the market for years and have expired patent protection will be included, while innovative drugs will not be part of this procurement [1] Group 2: Company Announcements and Developments - Xinhua Pharmaceutical's subsidiary received a Class III medical device registration certificate for a sterile saline solution for contact lens care [3] - Sanyou Medical announced that its spinal internal fixation connector system, JAZZSystem, received approval for market launch [4] - China National Pharmaceutical Group fully acquired Lixin Pharmaceutical for a consideration of up to $950.92 million [10] Group 3: Financial Performance - Baicheng Pharmaceutical expects a net profit of 0 to 6 million yuan for the first half of 2025, a decline of 95.53% to 100% year-on-year [6] - Kanglong Chemical anticipates a net profit of 67.92 million to 71.26 million yuan for the first half of 2025, a decrease of 36% to 39% year-on-year, despite a growth in core business [7] Group 4: Clinical Trials and Research - AstraZeneca's Baxdrostat achieved significant results in a Phase III clinical trial for patients with uncontrolled or resistant hypertension [13] - Hengrui Medicine reported positive results from a Phase III clinical trial of its GLP-1/GIP dual receptor agonist, HRS9531, showing a maximum weight reduction of 19.2% [14]

关于脊柱内固定连接器系统 JAZZ System 获得医疗器 械注册证的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海三友医疗器械股份有限公司（以下简称"公司"）于近日收到国家药品 监督管理局颁发的《中华人民共和国医疗器械注册证》，公司代理控股公司法国 Implanet 公司申报的三类医疗器械"脊柱内固定连接器系统 JAZZ System"注册 申请获得上市批准，现将相关情况公告如下： 一、医疗器械注册证内容 1、产品名称：脊柱内固定连接器系统 JAZZ System 证券代码：688085 证券简称：三友医疗 公告编号：2025-052 上海三友医疗器械股份有限公司 Implanet 公司是公司控股的一家法国骨科上市公司，其专注于脊柱内固定 拉力带产品的研发和销售，产品线覆盖 JAZZ 脊柱畸形拉力带系统，JAZZ 脊柱退 变系统和 JAZZ 骨折系统，可以治疗包括脊柱侧弯畸形、脊柱退变性疾病和部分 脊柱骨折等病症。同时 JAZZ 系列产品配有一系列精心设计的专用工具系统，用 于装配、连接、拉紧和调整 ...

Core Points - The company announced a cash dividend of 0.0042 CNY per share and a stock bonus of 0.2 shares for each share held, approved at the 2024 annual shareholders' meeting on May 23, 2025 [1][2][3] Distribution and Capital Increase Plan - The distribution year is set for 2024, targeting all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the equity registration [2] - The total share capital before the distribution is 277,885,415 shares, resulting in a total cash dividend payout of 1,167,118.7430 CNY (including tax) and an increase of 55,577,083 shares, leading to a new total share capital of 333,462,498 shares post-distribution [3][4] Implementation Dates and Methods - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited, with shareholders able to collect their dividends on the designated payment date [4] - For shareholders with unrestricted circulating shares, the cash dividends will be directly credited to their accounts based on their holdings as of the registration date [4] Taxation Details - For individual shareholders holding unrestricted shares for over one year, the cash dividend is exempt from personal income tax, while those holding for one year or less will have taxes calculated upon the sale of shares [7][8] - The actual cash dividend after tax for shareholders holding shares for less than one month is 0.00378 CNY per share, while those holding for more than one month but less than one year will have a tax burden of 10% [8][9] - The company will not withhold corporate income tax for other institutional investors, who must report and pay taxes according to regulations [10] Share Structure Changes - The company confirmed that all shares from the initial public offering strategic placement have been fully listed and circulated [11] - The diluted earnings per share for the fiscal year 2024, after the stock bonus, is projected to be 0.0344 CNY [12]

Key Points - The company has completed the listing and circulation of all shares from its initial strategic placement [1] - There is no differentiated dividend distribution plan involved [1] - The total share capital after the distribution and capital increase will be 333,462,498 shares [2][8] - The cash dividend per share is set at RMB 0.0042, and each shareholder will receive an additional 0.2 shares from capital reserves [2][4] - The total cash dividend distribution amounts to RMB 1,167,118.743 [2] - The company’s earnings per share for the fiscal year 2024, after the share increase, is projected to be RMB 0.0344 [8]

证券代码：688085 证券简称：三友医疗 公告编号：2025-051 上海三友医疗器械股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 3. 分配方案： 本次利润分配及转增股本以方案实施前的公司总股本277,885,415股为基数， 每股派发现金红利0.0042元（含税），以资本公积金向全体股东每股转增0.2股， 共计派发现金红利1,167,118.7430元（含税），转增55,577,083股，本次分配后总 股本为333,462,498股。 重要内容提示： | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | | --- | --- | --- | --- | | | | 通股份上市日 | | | 2025/7/16 | 2025/7/17 | 2025/7/17 | 2025/7/17 | 一、 通过分配、转增股本方案的股东会届次和日期 本次利润分配及转增股本方案经公司2025 年 5 月 23 日的2024年年度股东会审 议通过。 二、 分配、转增 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-050 上海三友医疗器械股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日召 开公司 2025 年第三次临时股东大会，选举产生了公司第四届董事会非职工代表 董事，与公司 2025 年 6 月 17 日召开职工代表大会选举产生的第四届董事会职工 代表董事任崇俊先生，共同组成了公司第四届董事会，任期自股东大会通过之日 起三年。2025 年 7 月 4 日，公司召开了第四届董事会第一次会议，审议通过了 《关于选举公司第四届董事会董事长的议案》、《关于选举公司第四届董事会专门 委员会委员的议案》、《关于聘任公司高级管理人员的议案》、《关于聘任公司证券 事务代表的议案》。现将具体情况公告如下： 一、董事会换届选举情况 （一）董事换届选举情况 上海三友医疗器械股份有限公司 关于完成董事会换届选举及聘任高级管理人员、证 券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2025 年 7 月 4 日召开公司 2025 年第三次临时股东大会 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-049 上海三友医疗器械股份有限公司 2025年第三次临时股东大会决议公告 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 48 | | --- | --- | | 普通股股东人数 | 48 | | 2、出席会议的股东所持有的表决权数量 | 86,402,369 | | 普通股股东所持有表决权数量 | 86,402,369 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 31.0928 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 31.0928 | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 （四） 表决方式是否符合《公司法》及公司章程的规定，股东大会主持情况等。 （一） 股东大会召开的时间：2025 年 7 月 4 日 （二） 股东 ...

北京市嘉源律师事务所 关于上海三友医疗器械股份有限公司 2025 年第三次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 E United Sales PT YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:上海三友医疗器械股份有限公司 北京市嘉源律师事务所 关于上海三友医疗器械股份有限公司 嘉源(2025)-04-514 北京市嘉源律师事务所(以下简称"本所")接受上海三友医疗器械股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《上市公司股东会规则》(以下简称"《股东会规则》")等现行有 效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及《上 海三友医疗器械股份有限公司章程》(以下简称"《公司章程》")的有关规定,指 派本所律师对公司 2025年第三次临时股东大会(以下简称"本次股东大会")进 行见证,并依法出具本法律意见书。 为出具本法律意见书,本 ...

Group 1 - Taotao Automotive expects a net profit of 310 million to 360 million yuan for the first half of 2025, representing a year-on-year increase of 70.34% to 97.81% [1] - The company specializes in the research, production, and sales of all-terrain vehicles, electric golf carts, electric scooters, electric balance bikes, electric bicycles, and their accessories [1] - China Communications Construction Company plans to repurchase shares worth between 500 million to 1 billion yuan, with a maximum repurchase price of 13.58 yuan per share [1][2] Group 2 - Annoqi's subsidiary received a government subsidy of 1.65 million yuan, accounting for 34.77% of the company's latest audited net profit [2] - Annoqi focuses on the research, production, and sales of mid-to-high-end differentiated dyes [3] - Minfeng Special Paper announced the complete shutdown of its Nanhu plant, as its Haiyan plant is now capable of handling the production capacity [4] Group 3 - Aoto Electronics received a trademark registration certificate from Saudi Arabia, covering various electronic products [5] - Landi Group plans to acquire up to 20.1667% of the shares of Jujia Technology for a total price not exceeding 121 million yuan [6][7] - Lifan Pharmaceutical's Danpi phenol raw material drug has been approved for market launch, utilizing a new process that enhances efficiency and meets market demand [8] Group 4 - Shanghai Construction received a total of 548 million yuan in government subsidies, which accounts for 22.79% of the company's latest audited net profit [8] - Wanbangde's subsidiary received ethical approval for a key clinical trial of a new drug for Alzheimer's disease [8] - Prolo Pharmaceutical's subsidiary received approval for the market launch of a new raw material drug for liver cancer treatment [9] Group 5 - Chenguang New Materials received a government subsidy of 26 million yuan, representing 62.86% of the company's latest audited net profit [10] - Sanyou Medical's subsidiary received a government subsidy of 331,000 yuan, accounting for 28.86% of the company's latest audited net profit [11] - Weichai Heavy Machinery expects a net profit of 132 million to 151 million yuan for the first half of 2025, reflecting a year-on-year increase of 40% to 60% [12] Group 6 - Guanhao Biological announced the termination of its application for a specific stock issuance [13] - China Film plans to use up to 1.5 billion yuan of idle funds for cash management [14] - Aotai Biological intends to use up to 480 million yuan of idle raised funds for cash management [15] Group 7 - Helin Micro-Nano is planning to issue overseas shares and list on the Hong Kong Stock Exchange [17] - Jinpan Technology's vice president resigned due to personal health reasons [18] - Tongyi Zhong's chairman and general manager plan to reduce their shareholdings in the company [19] Group 8 - Naipu Mining signed an overseas contract worth 18.85 million USD [21] - Zhengye Technology completed an asset sale transaction worth 178 million yuan [23] - Lianxin Equipment won a bid for a project worth 157 million yuan from BOE [24] Group 9 - Smart Control plans to apply for a comprehensive credit line of up to 260 million yuan from banks [25] - Keyuan Pharmaceutical's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [27] - Meige Intelligent's H-share listing application materials have been received by the China Securities Regulatory Commission [29] Group 10 - Siwei Tuxin's subsidiary submitted an H-share listing application [32] - Metro Design's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [32] - Aeston submitted an application for H-share listing [34] Group 11 - Jiu Ri New Materials' shareholders plan to reduce their holdings by a total of 98,900 shares [34] - Yihua Tong's shareholder plans to reduce their holdings by up to 700,000 shares [35] - Xishanghai plans to distribute a cash dividend of 0.08 yuan per share [36] Group 12 - Zhejiang Natural plans to distribute a cash dividend of 1.97 yuan for every 10 shares [37] - Kouzi Jiao plans to distribute a cash dividend of 1.30 yuan per share [38] - Huitong Group plans to distribute a cash dividend of 0.023 yuan per share [40] Group 13 - Tongyong Co. plans to reduce its holdings by up to 0.31% of the company's shares [41] - China Shenhua plans to distribute a cash dividend of 2.26 yuan for every 10 shares [43] - Huangting International's executive director resigned due to personal reasons [45] Group 14 - Jinkai New Energy plans to distribute a cash dividend of 1 yuan for every 10 shares [46] - Heimu Dan plans to distribute a cash dividend of 0.041 yuan per share [47] - Feiyada plans to acquire all or part of the controlling stake in Chang Kong Gear [48]